Optimizing Precision Measurements for Bladder Cancer Patients (2022)

March 4, 2022 to March 5, 2022

Johns Hopkins Greenberg Bladder Cancer Institute and American Urological Association Translational Research Collaboration

Optimizing Precision Measurements for Bladder Cancer Patients (2022) will be held virtually on  March 4-5, 2022.

The fifth annual translational research meeting provided by the American Urological Association and the Johns Hopkins Greenberg Bladder Cancer Institute will be a two-day, virtual symposium focused on the science and treatment of bladder cancer.  

Whole genome analyses conducted by The Cancer Genome Atlas network and private organizations produced comprehensive molecular portraits of primary urothelial cancers, and retrospective studies linked specific DNA alterations and gene expression profiles to patient prognoses and level of benefit from conventional chemotherapy and targeted therapies.  These biomarkers are now being evaluated prospectively as integral or integrated biomarkers in clinical trials, although controversy has emerged regarding their reliability.  In parallel, substantial progress has been made in the development of tests that measure candidate cancer biomarkers in blood or urine (“liquid biopsies”), and several tumor- and blood-based biomarkers have been linked to sensitivity or resistance to immunotherapy. 

A session entitled, “Discovery and Validation: Practical Challenges for Clinical Translation” will kick off the meeting by bringing together key government officials to discuss what is required to validate a candidate biomarker for integration into a NCTN clinical trial and to obtain FDA approval as a companion diagnostic.   Other meeting topics include: clinical trial design based on integral biomarkers, optimizing tumor-based biomarkers, emerging technologies, liquid biopsies, and the microbiome. The meeting will include a keynote lecture focused on the development of a pan-cancer plasma ctDNA assay for early detection and tissue site origin. 

NOTE: THE DEADLINE FOR REGISTRATION IS THURSDAY, MARCH 3 AT 12:OO PM EST. 

 

PROGRAM PLANNING COMMITTEE

  • David McConkey, PhD (Chair) - Johns Hopkins University Greenberg Bladder Cancer Institute
  • Woonyoung Choi, PhD, MS - Johns Hopkins University Greenberg Bladder Cancer Institute
  • Max Kates, MD - Johns Hopkins University Greenberg Bladder Cancer Institute
  • Jean Hoffman-Censits, MD - Johns Hopkins University Greenberg Bladder Cancer Institute
  • Sima Porten, MD, MPH - University of California San Francisco
  • Bishoy Faltas, MD - Weill Cornell Medicine
  • Joshua Meeks, MD, PhD - Northwestern University Feinberg School of Medicine
  • Cathy Mendelsohn, PhD - Columbia University

COURSE REGISTRATION FEES

Membership CategoryPrice

MD/PhD Member

$225

MD/PhD Non-Member

$275

Member Medical Student, Resident, Fellow

$150

Non-Member Medical Student, Resident, Fellow

$175

Employees of Industry

$450

Invited Faculty/Speakers

$0

Target Audience

  • Urologists
  • Research scientists
  • Clinical and research faculty
  • Clinical and postdoctoral fellows
  • Residents
  • Medical and graduate students
  • Medical professionals employed by industry

Learning Objectives

At the conclusion of this meeting, participants will be able to:

  1. Describe the state of the science in molecular biomarkers for bladder cancer
  2. Describe the established and emerging tissue-based molecular biomarkers for the selection of patients for treatment with conventional chemotherapy or immunotherapy and discuss their strengths and limitations.
  3. Evaluate the status of “liquid biopsies” for tracking local and systemic minimal residual disease (MRD).
  4. Explain emerging molecular imaging probes and the application of artificial intelligence and machine learning to conventional pathologic assessments.
  5. Explain patient perspectives on “reflex” somatic and germline DNA sequencing.
Course summary
Available credit: 
  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 Non-Physician Participation
Course opens: 
12/15/2021
Course expires: 
03/05/2025
Event starts: 
03/04/2022 - 12:00pm EST
Event ends: 
03/05/2022 - 3:30pm EST
Price:
$275.00
Rating: 
0

*agenda updates will be posted as they become available.
All times are listed in EST. 

Friday, March 4, 2022

12:00 PM

Welcome Remarks

David McConkey, PhD
Johns Hopkins Greenberg Bladder Cancer Institute

Taylor Monson
American Urological Association

 Session 1: Molecular Subtypes 

 

12:15 PMHistory/Overview

Gottfrid Sjodahl, PhD
Lund University

12:45 PMImpact of Decipher

Peter Black, MD
Vancouver Prostate Centre

1:15 PMQ&A
1:25 PMBreak
1:30 PMPlasticity - Role of PPARG

Cathy Mendelsohn, PhD
Columbia University

2:00 PMPlasticity - Role of Chromatin-modifying Enzymes

David Kwiatkowski, MD, PhD
Dana Farber/Harvard Cancer Center
Brigham And Women's Hospital

2:30 PMHeterogeneity

Noah Hahn, MD
Johns Hopkins Greenberg Bladder
Cancer Institute

3:00 PMQ&A
3:10 PMDay 1 Wrap Up
3:15 PMMeeting Concludes - Day 1

 

Saturday, March 5, 2022

11:00 AM

Welcome Remarks

David McConkey, PhD
Johns Hopkins Greenberg Bladder Cancer Institute

Taylor Monson
American Urological Association

 

Session 2: Predicting Benefit from Immunotherapy 

 

11:05 AMOverview

Thomas Powles, MD
Barts Cancer Centre/Cancer Research UK (CRUK)

11:35 AMBiology of Resistance

Matthew Galsky, MD
Icahn School of Medicine at Mount Sinai

12:05 PM

BCG

 

Woonyoung Choi, PhD, MS
Johns Hopkins Greenberg Bladder Cancer Institute

12:35 PMQ&A/Discussion
12:45 PMBreak
 

Session 3: Liquid Biopsies 

 

1:00 PMtDNA: History and Overview

Lars Dyrskjot Anderson, PhD
Aarhaus University

1:30 PMtDNA: Panels

Alex Wyatt, DPhil
Vancouver Prostate Centre

2:00 PMQ&A
2:10 PMUrine tDNA: UroSEEK

George Netto, MD
University of Alabama

2:40 PMUrine tDNA: Optimization

Phil Abbosh, MD, PhD
Fox Chase Cancer Center

3:10 PMQ&A/Discussion
3:20 PMMeeting Summary and Adjournment

David McConkey, PhD
Johns Hopkins Greenberg Bladder Cancer Institute

Taylor Monson
American Urological Association

3:30PMMeeting Concludes - Day 2

 

Optimizing Precision Measurements for Bladder Cancer Patients (2022) will be held virtually on  March 4-5, 2022.

Faculty disclosures will be posted here prior to the start of the course.

AUA ACCREDITATION INFORMATION

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 6.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

 

AUA PARTICIPANT INFORMATION & POLICIES

DISCLAIMER:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

COSENT TO USE OF PHOTOGRAPHIC IMAGES:

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

REPRODUCTION PERMISSION:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/DIETARY NEEDS: 

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 Non-Physician Participation

Price

Price:
$275.00
Please login or register to take this course.

NOTE: THE DEADLINE FOR REGISTRATION IS THURSDAY, MARCH 3 AT 12:OO PM EST. 

 

Registration Fees

Membership CategoryPrice

MD/PhD Member

$225

MD/PhD Non-Member

$275

Member Medical Student, Resident, Fellow

$150

Non-Member Medical Student, Resident, Fellow

$175

Employees of Industry

$450

Invited Faculty/Speakers

$0